Replimune Group, Inc.

NASDAQ: REPL · Healthcare · Biotechnology

PublicHQ Woburn, MA · MiddlesexCIK 0001737953Reports USD

#1 of 1,422 Healthcare companies by revenue

EA Score

——

FH 36DQ —GM —SS 67

v0.1 · 35/100 weight · pillars only

↑ market scale, workforce scale · ↓ return on equity, Piotroski F

Methodology →

Revenue TTM

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

-$313.9M

Employees

465

as of 2026-08-10

Market cap

$1.0B

as of 2026-08-10

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Net income-$313.9M-$313.9M2026

Operating income-$319.9M-$319.9M2026

Total assets$332.4M$332.4M2026

Liabilities$166.2M$166.2M2026

Equity$166.2M$166.2M2026

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

What is Replimune Group, Inc.’s financial profile?

Replimune Group, Inc. earned -$313.9M in FY2026 net income.

Peers · Healthcare

Latigo Biotherapeutics Inc.——Seaport Therapeutics, Inc. Common Stock——Olema Pharmaceuticals, Inc.——Alto Neuroscience, Inc.——Lumexa Imaging Holdings, Inc. Common Stock——Sana Biotechnology, Inc.——

Neighbors

Middlesex →

GE Vernova Inc.$38.1B63C Thermo Fisher Scientific Inc.$44.6B86A Analog Devices, Inc.$11.0B87A The TJX Companies, Inc.$60.4B85A Boston Scientific Corporation$20.1B88A Symbotic Inc.$2.2B49D

Key facts

CEOSushil Patel

SectorHealthcare

IndustryBiotechnology

HeadquartersWoburn, MA

ExchangeNASDAQ: REPL

Employees465

IPO date2018-07-20

Latest filings

10-Q2026-08-14 8-K2026-08-14 8-K2026-08-10 8-K2026-08-07 8-K2026-07-31 8-K2026-07-30 DEF 14A2026-07-29 10-K2026-06-29

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.